Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Albers, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Albers, G. W.

Stroke, Vol 23, 912-916, Copyright © 1992 by American Heart Association


ARTICLES

Role of ticlopidine for prevention of stroke

GW Albers
Stanford Stroke Center, Stanford University Medical Center, CA 94305.

BACKGROUND: Ticlopidine, an antiplatelet agent with a unique mechanism of action, is now available for clinical use in the United States and Canada. SUMMARY OF COMMENT: Recently two large randomized trials demonstrated that ticlopidine can reduce the risk of subsequent stroke in patients presenting with a transient ischemic attack or stroke. One study found that ticlopidine was more effective than aspirin for stroke prevention; however, it was less well tolerated than aspirin and was associated with severe but reversible neutropenia in almost 1% of patients. CONCLUSIONS: Ticlopidine is effective for both primary and secondary stroke prevention. It has a favorable risk/benefit ratio and is a particularly attractive option for patients who are unable to take aspirin.


This article has been cited by other articles:


Home page
ChestHome page
G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke
Chest, January 1, 2001; 119(1_suppl): 300S - 320S.
[Full Text] [PDF]


Home page
Circ. Res.Home page
A. Odawara, K. Kikkawa, M. Katoh, H. Toryu, T. Shimazaki, and Y. Sasaki
Inhibitory Effects of TA-993, a New 1,5-Benzothiazepine Derivative, on Platelet Aggregation
Circ. Res., April 1, 1996; 78(4): 643 - 649.
[Abstract] [Full Text]


Home page
StrokeHome page
T. Iwamoto, H. Kubo, and M. Takasaki
Platelet Activation in the Cerebral Circulation in Different Subtypes of Ischemic Stroke and Binswanger's Disease
Stroke, January 1, 1995; 26(1): 52 - 56.
[Abstract] [Full Text]